OBJECTIVE： To analyze the general patterns and characteristics of drug-induced lupus （DIL） induced by infliximab， and to provide reference for the safety of drug use. METHODS： Using “infiximab”，“lupus” as searching words， infliximab-induced DIL literatures included in CJFD， VIP and PubMed from Jan. 2002 to Jun. 2016 were retrieved and analyzed. RESULTS： Totally 30 effective literatures were retrieved， involving 31 DIL patients， there were 8 male cases （25.81％） and 23 female cases （74.19％）； 17 patients aged more than 50 （54.84％）. 20 cases occurred within 5-24 weeks （64.51％）. 16 patients received infliximab alone （51.61％）. Main clinical manifestations were skin rash or photosensitivie enteritig （15 cases）， joint pain （16 cases， multiple arthritis and synovitis） and fever （12 cases）. 5 patients suffered from 3 above symptoms simultaneously. Laboratory examination mainly manifested as antinuclear antibody， double stranded DNA antibody and anti-histone antibody positive. Thirty patients with DIL received drug withdrawal or steroid hormones treatment， among which the symptoms of 26 patients disappeared after drug withdrawal or treatment within 6 months， and 1 patient deteriorated. CONCLUSIONS： DIL-induced by infliximab invovle patients’age and gender， disease types， family history and other factors. Clinicians should be aware of rules and characteristics of DIL induced by infliximab， and tighten drug use monitoring to reduce ADR.